Nervgen Pharma Corp (TSE:NGEN) has released an update.
NervGen Pharma Corp. has announced a delay in Q1 2024 for the enrollment of their chronic cohort in a clinical trial for spinal cord injury treatment due to recruitment challenges, but has completed a CA$23 million financing to extend its cash runway through Q3 2025. The company is amending the subacute cohort’s protocol to improve feasibility and reduce participant burden, while also preparing to launch an open-label study for placebo recipients pending efficacy signals and regulatory approval.
For further insights into TSE:NGEN stock, check out TipRanks’ Stock Analysis page.
